Annual review of KRAS inhibitors in 2022-Reference-Cited by-同舟云学术

Annual review of KRAS inhibitors in 2022

Published:2023-03 Issue: Volume:249 Page:115124
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Wang Hao,Chi Lingling,Yu Fuqiang,Dai Honglin,Gao Chao,Si Xiaojie,Wang Zhengjie,Liu Limin,Zheng Jiaxin,Shan Lihong^ORCID,Liu Hongmin,Zhang Qiurong^ORCID

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference64 articles.

1. Ras oncogenes: split personalities;Karnoub;Nat. Rev. Mol. Cell Biol.,2008

2. Drugging the undruggable RAS: mission possible?;Cox;Nat. Rev. Drug Discov.,2014

3. Targeting mutated GTPase KRAS in tumor therapies;Fan;Eur. J. Med. Chem.,2021

4. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations;Capon;Nature,1983

5. Drugging KRAS: current perspectives and state-of-art review;Parikh;J. Hematol. Oncol.,2022

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer;Cell Death & Disease;2024-08-31

2. Insight into structural dynamics involved in activation mechanism of full length KRAS wild type and P-loop mutants;Heliyon;2024-08

3. Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display;Bioorganic & Medicinal Chemistry;2024-08

4. Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells;Acta Pharmaceutica Sinica B;2024-08

5. In Silico Identification of Dysregulated miRNAs Targeting KRAS Gene in Pancreatic Cancer;Diseases;2024-07-12